SG10201811361XA - Treatment of polybacterials infections - Google Patents
Treatment of polybacterials infectionsInfo
- Publication number
- SG10201811361XA SG10201811361XA SG10201811361XA SG10201811361XA SG10201811361XA SG 10201811361X A SG10201811361X A SG 10201811361XA SG 10201811361X A SG10201811361X A SG 10201811361XA SG 10201811361X A SG10201811361X A SG 10201811361XA SG 10201811361X A SG10201811361X A SG 10201811361XA
- Authority
- SG
- Singapore
- Prior art keywords
- infections
- polybacterial
- antibody
- specifically binds
- pseudomonas aeruginosa
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108010092231 staphylococcal alpha-toxin Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRA CT Provided herein are me thods of preventing and treating polybacterial infections com prising administering an effective am ount of an antibody or antigen - binding fragment thereof that specifically binds to an epitope produced by a t least one of the bacterium in the polybacterial infection. For example, an antibody that specifically binds to Staphy lococcus aureus alpha toxin can be adm inistered to a patient with a polybacterial infection comprising Staphylococcus aureus and Pseudomonas aeruginosa to inhibit the growth of Pseudomonas aeruginosa. [F IG.]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462014506P | 2014-06-19 | 2014-06-19 | |
US201562140849P | 2015-03-31 | 2015-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201811361XA true SG10201811361XA (en) | 2019-01-30 |
Family
ID=54936121
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201811361XA SG10201811361XA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
SG11201609652RA SG11201609652RA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201609652RA SG11201609652RA (en) | 2014-06-19 | 2015-06-19 | Treatment of polybacterials infections |
Country Status (10)
Country | Link |
---|---|
US (1) | US11168132B2 (en) |
EP (1) | EP3157565B1 (en) |
JP (2) | JP6845016B2 (en) |
KR (1) | KR102549870B1 (en) |
CN (1) | CN106456767B (en) |
AU (1) | AU2015276938B2 (en) |
CA (1) | CA2952278A1 (en) |
SG (2) | SG10201811361XA (en) |
TW (1) | TWI719938B (en) |
WO (1) | WO2015196011A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170807A2 (en) | 2011-06-10 | 2012-12-13 | Medimmune, Llc | Anti-pseudomonas psl binding molecules and uses thereof |
SI2776065T1 (en) | 2011-11-07 | 2020-10-30 | Medimmune Limited | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
SG11201503231YA (en) | 2012-11-06 | 2015-05-28 | Medimmune Llc | METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES |
SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
JP7110095B2 (en) | 2015-11-30 | 2022-08-01 | メドイミューン・リミテッド | How to prevent or treat nosocomial pneumonia |
US20190153076A1 (en) * | 2016-05-05 | 2019-05-23 | The Trustees Of The University Of Pennsylvania | DNA Antibody Constructs for Use against Pseudomonas Aeuruginosa |
TW202311284A (en) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | Human antibodies to s. aureus hemolysin a toxin |
CA3107463A1 (en) | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
TW202028232A (en) | 2018-10-09 | 2020-08-01 | 美商麥迪紐有限責任公司 | Antibodies directed against staphylococcus aureus leukotoxins |
TW202035443A (en) | 2018-10-09 | 2020-10-01 | 美商麥迪紐有限責任公司 | Combinations of anti-staphylococcus aureus antibodies |
GB201816554D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
WO2021015237A1 (en) * | 2019-07-24 | 2021-01-28 | 国立研究開発法人科学技術振興機構 | Innovative production technique for antibody-enzyme |
FR3114970B1 (en) | 2020-10-08 | 2023-06-30 | Univ Tours | COMBINATION OF INHALED ANTIBODIES WITH IMMUNO-MODULATING AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2655133C (en) | 2006-06-12 | 2018-03-20 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
US8642039B2 (en) * | 2009-12-22 | 2014-02-04 | Kalobios Pharmaceuticals, Inc. | Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection |
CA2826566C (en) * | 2011-02-08 | 2022-09-13 | Medimmune, Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
SI2776065T1 (en) | 2011-11-07 | 2020-10-30 | Medimmune Limited | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
SG11201503231YA (en) | 2012-11-06 | 2015-05-28 | Medimmune Llc | METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES |
JP2015535005A (en) * | 2012-11-06 | 2015-12-07 | メディミューン,エルエルシー | Combination therapy with anti-Pseudomonas Psl and PcrV binding molecules |
SG11201503232TA (en) | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
-
2015
- 2015-06-18 TW TW104119861A patent/TWI719938B/en active
- 2015-06-19 SG SG10201811361XA patent/SG10201811361XA/en unknown
- 2015-06-19 JP JP2016573926A patent/JP6845016B2/en active Active
- 2015-06-19 EP EP15809174.4A patent/EP3157565B1/en active Active
- 2015-06-19 KR KR1020167034742A patent/KR102549870B1/en active IP Right Grant
- 2015-06-19 US US15/319,958 patent/US11168132B2/en active Active
- 2015-06-19 CA CA2952278A patent/CA2952278A1/en active Pending
- 2015-06-19 AU AU2015276938A patent/AU2015276938B2/en active Active
- 2015-06-19 CN CN201580032548.7A patent/CN106456767B/en active Active
- 2015-06-19 WO PCT/US2015/036576 patent/WO2015196011A1/en active Application Filing
- 2015-06-19 SG SG11201609652RA patent/SG11201609652RA/en unknown
-
2020
- 2020-12-18 JP JP2020209896A patent/JP2021063090A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015196011A1 (en) | 2015-12-23 |
SG11201609652RA (en) | 2016-12-29 |
JP2017519768A (en) | 2017-07-20 |
KR20170015329A (en) | 2017-02-08 |
EP3157565B1 (en) | 2024-04-24 |
EP3157565A4 (en) | 2018-03-21 |
KR102549870B1 (en) | 2023-06-29 |
TW201613575A (en) | 2016-04-16 |
AU2015276938A1 (en) | 2017-01-05 |
CN106456767A (en) | 2017-02-22 |
US20170129943A1 (en) | 2017-05-11 |
EP3157565A1 (en) | 2017-04-26 |
US11168132B2 (en) | 2021-11-09 |
JP6845016B2 (en) | 2021-03-17 |
JP2021063090A (en) | 2021-04-22 |
AU2015276938B2 (en) | 2020-11-19 |
TWI719938B (en) | 2021-03-01 |
CN106456767B (en) | 2021-07-09 |
CA2952278A1 (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201811361XA (en) | Treatment of polybacterials infections | |
PH12018501429A1 (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
WO2017075188A3 (en) | Methods of using anti-alpha toxin antibody | |
PH12016501577A1 (en) | Monobactam organic compounds for the treatment of bacterial infections | |
MX2019007784A (en) | Human antibodies to s. aureus hemolysin a toxin. | |
MX2019007613A (en) | Combination therapy with amidine substituted ã-lactam compounds and ã-lactamase inhibitors for infections with antibiotic resistant bacterial strains. | |
MX2016007533A (en) | Compositions and methods for phagocyte delivery of anti-staphylococcal agents. | |
MX363678B (en) | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections. | |
BR112017011478A2 (en) | antibody-antibiotic conjugate compound, antibody-antibiotic conjugate, pharmaceutical composition, methods of treating a bacterial infection and exterminating staph aureus, process for compound preparation, kit and antibiotic-binder intermediate | |
PH12019500360A1 (en) | Antibiotic compounds | |
MX2021002719A (en) | Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains. | |
WO2016142445A3 (en) | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection | |
EP3932917A3 (en) | Substituted phenyloxazolidinones for antimicrobial therapy | |
ZA202002093B (en) | Antibacterial compounds | |
MX2019011908A (en) | Anti-bacterial peptide macrocycles and use thereof. | |
AU2012335397A8 (en) | Novel bacteriophages | |
MX366894B (en) | ANTIMICROBIAL COMPOSITIONS and METHODS FOR THEIR PRODUCTION. | |
WO2017137954A3 (en) | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease | |
MX2018011095A (en) | Carbapenem compounds. | |
AU2018257122A1 (en) | Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof | |
WO2015100448A3 (en) | Multimodal antimicrobial therapy | |
CO2021015337A2 (en) | Methods and compositions comprising Staphylococcal protein a variants (spa) | |
BR112017022864A2 (en) | antibacterial compositions | |
EA202290048A1 (en) | MEDICINE AND ITS USE FOR THE TREATMENT OF BACTERIAL INFECTIONS ASSOCIATED WITH BIOFILM | |
WO2019025803A3 (en) | An antimicrobial composition |